Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 10, 2005. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary Shares by six individuals through the Company's ShareReward Plan on October 6, 2005. The shares were purchased at a price of GBP 14.56 per Ordinary Share under the Dividend Reinvestment element of the Plan, which was entered into on October 5, 2001.
- Mr J S Heslop: Acquisition of 6 Ordinary Shares
- Mr R Bondy: Acquisition of 6 Ordinary Shares
- Dr D Pulman: Acquisition of 5 Ordinary Shares
- Mr C Viehbacher: Acquisition of 2 Ordinary Shares
- Mrs J V Younger: Acquisition of 6 Ordinary Shares
- Mr A P Witty: Acquisition of 6 Ordinary Shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the statutory notification of the share transactions described above in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Investor Verification Points
- Verify the share price of GBP 14.56 per Ordinary Share on October 6, 2005.
- Confirm the total number of shares acquired by the listed directors and managers (31 shares total).
- Review the terms of the ShareReward Plan entered into on October 5, 2001, to understand the Dividend Reinvestment mechanism.